Survey - Pyloshot-H.Pylori & Functional dyspepsiaMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File “Role of Helicobacter pylori in Functional Dyspepsia:Real-World HCP Insights and the Impact of Postbiotics as Adjunctive Therapy”1. Approximately how many patients with Functional Dyspepsia (FD) do you manage in a typical month? More than 50 30–50 10–30 Less than 102. Approximately what proportion of your Functional Dyspepsia patients test positive for H. pylori? More than 75% 50–75% 25–50% Less than 25%3. In which Functional Dyspepsia patient profile do you most strongly suspect H. pylori involvement? Persistent epigastric pain Post-prandial fullness/early satiety Recurrent dyspepsia despite acid suppression Recurrent symptoms after previous treatment4. Do you believe H. pylori eradication significantly improves symptoms in appropriately selected FD patients? Yes No5. What is your preferred approach for evaluating H. pylori in patients with Functional Dyspepsia? Test-and-treat strategy Endoscopy-based evaluation Empirical treatment in selected patients Evaluate only after failure of initial therapy6. What is the biggest challenge in managing H. pylori-associated Functional Dyspepsia? Persistent symptoms despite eradication Antibiotic resistance Poor patient adherence Recurrence after treatment7. What primarily causes persistent FD symptoms after eradication? Residual mucosal micro-inflammation Post-antibiotic dysbiosis Visceral hypersensitivity / brain-gut axis Impaired gastric motility8. Which outcome best defines successful management of Functional Dyspepsia associated with H. pylori? Complete symptom relief Sustained symptom improvement Prevention of recurrence Improved quality of life9. Which aspect of Functional Dyspepsia management do you believe remains inadequately addressed by standard H. pylori eradication therapy alone? Persistent dyspeptic symptoms Antibiotic-related gastrointestinal adverse effects Gastric mucosal recovery Long-term recurrence prevention10. Following successful H. pylori eradication, which unmet need do you encounter most frequently in Functional Dyspepsia patients? Persistent dyspeptic symptoms Recurrence of symptoms Gastric mucosal recovery takes longer than expected Reduced patient adherence due to antibiotic-related adverse effects11. Which clinical benefit would make you most likely to consider adjunctive Lactobacillus reuteri DSM 17648 during standard H. pylori eradication therapy? Improved eradication success Better relief of Functional Dyspepsia symptoms Reduction in antibiotic-associated gastrointestinal adverse effects Improved gastric mucosal healing and recovery12. In your opinion, where can Lactobacillus reuteri DSM 17648 provide the greatest value as an adjunct to standard H. pylori eradication therapy? Supporting eradication effectiveness Improving patient tolerability and adherence Enhancing long-term gastric health Addressing multiple treatment goals simultaneously I have read and agree to the Terms and Conditions .Submit Form